Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Galanin receptor 1 is a seven-transmembrane domain G protein-coupled receptor encoded by the GALR1 gene, widely expressed in the brain, spinal cord, heart, and intestine[3][4]. It mediates neuropeptide galanin’s effects—primarily via inhibitory Gi/Go protein signaling—which suppresses cyclic AMP production and regulates neural excitability, mood, pain, and endocrine secretion. GALR1 plays roles both in health (neural modulation, mood, sleep, antinociception) and disease (cancer, epilepsy, depression, inflammation). Its structure has been resolved in complex with galanin and G proteins, revealing a unique extracellular helical ligand-binding mode and distinctive G-protein interface[1][5][6]. The zinc ion inhibits GALR1 function as a negative allosteric modulator[5][6][7].
Ligand binding to GALR1 leads to Gi/Go protein activation, resulting in inhibition of adenylate cyclase and decreased cAMP. Modulation of MAPK signaling via βγ subunit downstream effects. Allosteric modulation (notably by zinc ions as negative regulators).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Galanin receptor 1 (GALR1).